Drug intelligence / Profile preview

TLR4 shRNA

Development stage
Preclinical
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01

Overview

TLR4 shRNA (Toll-like receptor 4 short hairpin RNA) is a sequence-specific RNA interference (RNAi) agent designed to silence the expression of Toll-like receptor 4 (TLR4). TLR4 is a pattern recognition receptor that plays a critical role in initiating innate immune responses and inflammatory cascades. In various preclinical models, TLR4 shRNA has been investigated for its therapeutic potential in mitigating inflammatory and apoptotic processes. For instance, in diabetic mouse models, gene silencing of TLR4 has been shown to attenuate myocardial apoptosis and downregulate pro-apoptotic cascades involving caspase-3, caspase-8, and Fas. Additionally, TLR4 shRNA has been explored in research settings for its ability to inhibit hepatic stellate cell activation in liver fibrosis, suppress tumor growth in cervical cancer, and reduce the stemness of glioma cancer stem cells. TLR4 shRNA is primarily utilized as a research-use-only laboratory tool to study TLR4-mediated signaling pathways.

Other names
TLR4 short hairpin RNATLR-4 short hairpin RNATLR 4 short hairpin RNATLR4-shRNATLR-4-shRNATLR 4-shRNAToll-like receptor 4 shRNAsh-TLR4sh-TLR-4sh-TLR 4shTLR4shTLR-4shTLR 4
02

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on TLR4 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLR4 shRNA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call